In our small cohort, we observe homogeneity among driver mutations such as within KRAS and TP53, which in isolation are supportive of the model of pancreatic cancer evolution that describes a punctuated course with early, clonal events. This evidence concerns the gene KRAS and pancreatic neoplasm.